---
$id: https://graph.org.ai/products/commodity/51131733
$type: Product
source: UNSPSC
code: "51131733"
title: "Naroparcil"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Naroparcil

**UNSPSC Code**: 51131733
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a thrombolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 238M5105OY. European Medicines Agency schedules Naroparcil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09166MIG. Naroparcil generally arises in the molecular formula C19H17NO4S2. The term NAROPARCIL is an International Non-Proprietary Name or INN. NAROPARCIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naroparcil under HS 29349990 and SITC 51579. As of Q4 2014, NAROPARCIL remains the US FDA Preferred Term for this commodity. Naroparcil bears US NLM identifiers UMLS ID C0294245 and NCI Concept Code C66219. SMILES: S1C(SC2CCC(CC2)C(=O)C2CCC(CC2)C#N)C(O)C(O)C(O)C1.

